🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Locally Advanced

A Phase I First-in-Human Study of GenSci128 in Patients With Solid Tumors Harboring a TP53 Y220C Mutation NCT06908434Phase 11 site📍 Shanghai Changchun GeneScience Pharmaceutical Co., Ltd. · Tests: GenSci128 tablets SCRT VS LCRT Followed by PD-L1 Inhibitor Plus CAPEOX as TNT in Patients With LARC NCT07284992Phase 21 site📍 Jinan Shandong Provincial Hospital · Tests: short-term radiotherapy combined with Adebrelimab and capox, long-term radiotherapy combined with Adebrelimab and capox A Study of TY-2699a in Patients With Locally Advanced or Metastatic Solid Tumors NCT05866692Phase 12 sites📍 Beijing📍 Jinan TYK Medicines, Inc · Tests: TY-2699a Trilaciclib in Combination With Docetaxel for Second-Line and Beyond Treatment of Locally Advanced or Metastatic NSCLC NCT06929936Phase 21 site📍 Xiamen The First Affiliated Hospital of Xiamen University · Tests: Trilaciclib combined with Docetaxel VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma NCT03556228Phase 1, Phase 215 sites📍 Santa Rosa📍 Hartford📍 Washington D.C. VM Oncology, LLC · Tests: VMD-928 100 mg Tablet, VMD-928 Tablet and Pembrolizumab (200 mg) A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. NCT07062965Phase 3433 sites📍 Anchorage📍 Chandler📍 Gilbert Pfizer · Tests: PF-07248144, Fulvestrant, Everolimus, Exemestane Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06) NCT06780111Phase 1, Phase 252 sites📍 Pittsburgh📍 Natal📍 Porto Alegre Merck Sharp & Dohme LLC · Tests: Pembrolizumab, I-DXd, Leucovorin, Levoleucovorin, 5-Fluorouracil (5-FU) A Clinical Trial Evaluating TQB2102 for Injection in Combination With Behmosubaisumab/Payamprolizumab With or Without Chemotherapy in Unresectable Locally Advanced, Recurrent, or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastroesophageal Adenocarcinoma NCT06767800Phase 239 sites📍 Fuyang📍 Lu'an📍 Maanshan Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Phar… · Tests: TQB2102 for injection (7.5 mg) +Benmelstobart+Chemotherapy, TQB2102 for injection (6 mg/7.5 mg) +Benmelstobart+Chemothe… Aspects of Quality of Life During Adjuvant Oncological Treatment for Locally Advanced Lung Cancer Which Include Immune Checkpoint Inhibitor. NCT07754409n/a1 site📍 Gothenburg Göteborg University Postoperative Radiotherapy Followed by Immunotherapy for Locally Advanced Esophageal Carcinoma NCT05937438Phase 1, Phase 21 site📍 Hefei Anhui Provincial Hospital · Tests: Immune Checkpoint Inhibitors Circulating and Urine Tumor DNA Dynamics Predict Minimal Residual Disease and Recurrence Risk in Locally Advanced Upper Tract Urothelial Carcinoma NCT05595408n/a1 site📍 Shanghai RenJi Hospital · Tests: Adjuvant chemotherapy, adjuvant immunotherapy A Phase II Study of Toripalimab Combined With Sequential Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell Carcinoma NCT06843889Phase 21 site📍 Guangzhou Nanfang Hospital, Southern Medical University · Tests: Toripalimab (240mg day1, Q3W*3cycle) NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC NCT06405490Phase 21 site📍 Beijing Cancer Institute and Hospital, Chinese Academy of Medical S… · Tests: Nanoliposomal Irinotecan+Oxaliplatin +Capecitabine+Cadonilimab A Study of Tucatinib and Trastuzumab in People With Rectal Cancer NCT05672524Phase 27 sites📍 Basking Ridge📍 Middletown📍 Montvale Memorial Sloan Kettering Cancer Center · Tests: Trastuzumab, Tucatinib A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement NCT07359820Phase 219 sites📍 Phoenix📍 Jacksonville📍 Tampa Elevar Therapeutics · Tests: Lirafugratinib Serplulimab Combined With Induction Chemotherapy and Radiotherapy in Nasopharyngeal Carcinoma NCT07177443Phase 31 site📍 Wuhan Union Hospital, Tongji Medical College, Huazhong University… · Tests: Radiotherapy, Serplulimab, Cisplatin A Phase II Study of GFH375 Combined With GFS202A or GFH276 Versus GFH375 in Patients With Previously Treated Locally Advanced Unresectable or Metastatic Pancreatic Cancer Harboring KRAS G12D Mutation NCT07784374Phase 21 site📍 Shanghai Genfleet Therapeutics (Shanghai) Inc. · Tests: GFH375, GFH276, GFS202A Study Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Biomarker Analysis to Characterize Response/Resistance NCT07483983Phase 27 sites📍 Villejuif📍 Bordeaux📍 Dijon Gustave Roussy, Cancer Campus, Grand Paris · Tests: ASP3082 Randomized Study of Carbon Ion Boost in Hypoxic Lesions for Locally Advanced Non-small Cell Lung Cancer NCT06205927Phase 21 site📍 Shanghai Jian Chen · Tests: Standard carbon ion beam radiotherapy, Carbon ion beam radiotherapy simultaneously dose boost Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After Chemoradiotherapy NCT05892354NA20 sites📍 Fuzhou📍 Fuzhou📍 Guangzhou First Affiliated Hospital of Guangxi Medical University · Tests: Enteral immunonutrition, Standard enteral nutrition Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology NCT05756569Phase 24 sites📍 Atlanta📍 Atlanta📍 Atlanta Emory University · Tests: Biospecimen Collection, Computed Tomography, Enfortumab Vedotin, Magnetic Resonance Imaging, Pembrolizumab Organ Preservation in Locally Advanced Rectal Cancer NCT03064646NA1 site📍 Elche Fundación para el Fomento de la Investigación Sanitaria y B… · Tests: Organ Preservation Conversion Therapy With RC48, Sintilimab, and SOX for HER2 1+/2+ Unresectable Gastric Cancer NCT07194005Phase 21 site📍 Shanghai Fudan University · Tests: Disitamab vedotin(RC48), Sintilimab, S-1, Oxaliplatin Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell Carcinoma NCT06988956Phase 21 site📍 Nanjing The First Affiliated Hospital with Nanjing Medical Universi… · Tests: Nimotuzumab, Tegafur, radiotherapy SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer NCT07464756Phase 21 site📍 Nanjing The First Affiliated Hospital with Nanjing Medical Universi… · Tests: SHR-1701, apatinib, S-1 & Oxaliplatin PG2 Injection for the Treatment of moderate-to Severe Fatigue in Breast Cancer Patients NCT05440227Phase 21 site📍 Taipei PhytoHealth Corporation · Tests: PG2 Lyo. Injection 500mg, Placebo 0.9% normal saline Efficacy and Safety of Penpulimab Combined With Anlotinib and Chemotherapy NCT06586242Phase 21 site📍 Xi'an Xijing Hospital · Tests: Penpulimab;Anlotinib;albumin paclitaxel;oxaliplatin;lobaplatin I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer NCT01042379Phase 242 sites📍 Birmingham📍 Scottsdale📍 Tucson QuantumLeap Healthcare Collaborative · Tests: Standard Therapy, AMG 386 with or without Trastuzumab, AMG 479 (Ganitumab) plus Metformin, MK-2206 with or without Tras… Total Neoadjuvant Treatment With or Without Tislelizumab for Locally Advanced Rectal Cancer. NCT06940388Phase 22 sites📍 Mainz📍 Petah Tikva brenner baruch · Tests: Tislelizumab, Total neoadjuvant therapy (TNT) Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer NCT06928389Phase 31 site📍 Shanghai Akeso · Tests: Ivonescimab, docetaxel, Placebo, docetaxel
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy